AcquisitionOther
Ambrx Biopharma, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Ambrx Biopharma, Inc. -> target · $28.00
Through this transaction, we will continue to advance our leading prostate cancer candidate and Ambrxs promising pipeline, while delivering significant and certain cash value to our shareholders.
Open source record (SEC) ↗